Drug Development
  • Subscriptions
  • Current/Back Issues
  • Market News & Trends
  • Executive Interviews

Select a Section
  • Analytical/Testing
  • Bioavailability & Solubility
  • Bio Platforms
  • Drug Delivery
  • Devices
  • Excipients
  • Formulation Development
  • Contract Services
Analytical Testing, Contract Services, Formulation Development, Market News & Trends

WuXi STA to Build New R&D Center


STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), recently announced it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center. The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate their projects from preclinical to commercial stage.

WuXi STA has already established an industry leading process development platform with over 1,000 scientists and five sites located in China and the United States.  The company’s Jinshan site currently focuses on manufacturing innovative Active Pharmaceutical Ingredients (APIs) and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the US FDA.

The new R&D center will be located next to the existing Jinshan drug substance manufacturing site, adding more than 30,000 square meters of laboratory space and 500 scientists. Upon completion, the expanded Jinshan campus will be able to offer an integrated one-site solution for partners to push forward innovative APIs and advanced intermediates – from preclinical and clinical development through to global commercial launch. The new campus will also provide access to industry-leading technology platforms such as flow chemistry, biocatalysis, and high potency from laboratory to commercial scale.

Shanghai Jinshan District has enjoyed sustained economic growth in recent years, via its strategic focus on “smart manufacturing”, and has attracted many biotechnology and pharmaceutical companies including WuXi STA.

“This new R&D center in Caojing Town, Jinshan is a result of the long term ‘win-win’ collaboration between the Jinshan government and WuXi STA. The project will further strengthen the life science industry ecosystem in Jinshan District,” said Mr. Quanquan Zhang, Vice Governor of Jinshan.

“The new R&D center is a reflection of our commitment to better serve customers worldwide and support growth in the local economy, as well as the biopharmaceutical ecosystem in Jinshan,” added Dr. Minzhang Chen, CEO of WuXi STA. “As we continuously strengthen the capability and capacity of our platform, we will enable more global partners to shorten development timelines and lower the cost of new drug development, improving the lives of people around the world.”

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for Active Pharmaceutical Ingredients (APIs) and finished dosage forms. For more information, visit www.STApharma.com.

Total Page Views: 333


VIDEO SPOTLIGHT

COMPANY PROFILES

  • AbbVie Contract Manufacturing
  • ABITEC Corporation
  • Ajinomoto Bio-Pharma Services
  • Alcami
  • Ascendia Pharmaceuticals
  • BASF Corporation
  • Baxter BioPharma Solutions
  • BD Medical – Pharmaceutical Systems
  • BioDuro
  • Cambrex
  • Capsugel – Lonza
  • Captisol, a Ligand Company
  • Catalent Pharma Solutions
  • CordenPharma International
  • CPhI North America
  • Credence MedSystems, Inc
  • Croda Health Care
  • Drug Delivery Experts
  • EG-GILERO
  • Enable Injections
  • Evonik Industries AG
  • Exelead
  • Frontage
  • Gateway Analytical LLC
  • Gattefosse
  • Hovione
  • JRF Global
  • Lonza Pharma & Biotech
  • Metrics Contract Services
  • MilliporeSigma
  • Mitsubishi Gas Chemical Company, Inc.
  • Nemera
  • Noble
  • PCI Pharma Services
  • Pfanstiehl
  • Pfizer CentreOne
  • PharmaCircle
  • Portal Instruments
  • ProMed Pharma, LLC
  • SGS Life Sciences
  • SGW Pharma Marketing
  • SHL Group
  • UPM Pharmaceuticals
  • Vetter Pharma International
  • West Pharmaceutical Services

INDUSTRY EVENTS

4th Annual Drug Development Networking Summit
April 11, 2019, Bridgewater, NJ

AAPS
Nov 3-6, 2019, San Antonio, TX

BIO 2019
June 3-6, 2019, Philadelphia, PA

BIO Asia International Conference
March 5-6, 2019 Tokyo, Japan

Controlled Release Society Meeting
July 21-24, 2019, Valencia, Spain

CPhI North America
April 30-May 2, 2019, Chicago, IL

CPhI Worldwide
November 5-7, 2019, Frankfurt, Germany

INTERPHEX
April 2-4, 2019, New York City, NY

PDA Annual Meeting
March 11-13, 2019, San Diego, CA

RDD (Respiratory Drug Delivery)
May 7-10, 2019, Lisbon, Portugal

Universe of Prefilled Syringes & Injection Devices
October 22-23, Gothenburg, Sweden

MARKET SEGMENTS

  • Analytical/Testing
  • Bioavailability & Solubility
  • Bio Platforms
  • Drug Delivery
  • Devices
  • Excipients
  • Formulation Development
  • Contract Services

CORPORATE

  • SUBMISSION GUIDELINES
  • ABOUT US
  • BACK ISSUES
  • MEDIA PLANNER
  • CONTACT
  • FREE PRINT SUBSCRIPTION

DRUG DEVELOPMENT & DELIVERY
219 Changebridge Road
Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937

Copyright © 2018 Drug Development & Delivery. All Rights Reserved. Privacy Policy / Terms and Conditions
This material may not be published, broadcast, rewritten, or redistributed without permission.
Web design and development by WalkerTek.